Latest Pancreatic Cancer Articles

Image representing Celgene as depicted in Crun...

Image via CrunchBase

During the recent ASCO GI conference, the big news was the release of the results of the Abraxane trials.  The data show that the lives of pancreatic cancer patients can be extended by two months when adding Abraxane into the standard gemcitabine treatment regimen.

Sally Church at the PharmaStrategy blog gave a good overview of the conference, and included an interview with Dr. Hedy Lee Kindler who gave us the clinicians perspective on the Abraxane results.

In addition to this Congress signed off on the Recalcitrant Cancer Research Act which provides funding for traditionally under funded diseases like Pancreatic Cancer.



Here are the latest additions to the Mendeley Pancreatic Cancer Genomics collection.


About Mark Fortner

I write software for scientists doing drug discovery and cancer research. I'm interested in Design Thinking, Agile Software Development, Web Components, Java, Javascript, Groovy, Grails, MongoDB, Firebase, microservices, the Semantic Web Drug Discovery and Cancer Biology.
This entry was posted in Drug Development, pancreatic cancer and tagged , , , , . Bookmark the permalink.

Leave a Reply

Fill in your details below or click an icon to log in: Logo

You are commenting using your account. Log Out /  Change )

Google+ photo

You are commenting using your Google+ account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )


Connecting to %s